Exciting Developments in Precision Oncology
Caris Life Sciences, a patient-centric AI TechBio company, has achieved a remarkable milestone with its FDA-approved MI Cancer Seek®. This innovative assay is paving the way for more accurate cancer diagnostics and targeted therapies. The validation, recently published in the journal Oncotarget, reaffirms the significant analytical and clinical performance of MI Cancer Seek, making it an essential tool for identifying cancer patients who can benefit from personalized treatment options.
Revolutionizing Cancer Detection
MI Cancer Seek stands out as the first test to integrate whole exome sequencing (WES) and whole transcriptome sequencing (WTS) along with companion diagnostic indications specifically for solid tumors in both adults and children. This pioneering approach signifies a substantial leap in the field of precision oncology, allowing for a broader understanding of tumor biology. The assay excels in detecting various high clinical significance variants and adheres to stringent laboratory standards, reflecting its reliability.
The study highlights that MI Cancer Seek has demonstrated impressive performance metrics, with positive and negative percent agreement ranging from 97% to 100% when compared to other FDA-approved assays. Furthermore, it allows simultaneous RNA and DNA extraction from a minimal tissue sample, reducing the need for multiple testing processes and avoiding delays that can arise from increased tissue requirements.
Encouraging Words from Experts
David Spetzler, President of Caris, emphasizes the importance of MI Cancer Seek, stating, "This assay provides a comprehensive molecular blueprint that saves tissue without compromising results. The study results reflect our dedication to scientific integrity and validation." This commitment resonates with patients and healthcare providers who rely on advanced molecular profiling assays to make informed treatment decisions.
George W. Sledge, Jr., MD, Chief Medical Officer at Caris, adds, "Broad-based biomarker panels are essential for improving outcomes in precision medicine. Yet, a significant number of patients do not have access to comprehensive molecular profiling. By integrating companion diagnostics into multi-gene panels, we aim to maximize the utility of tissue samples available for testing, helping more patients access personalized therapies." This patient-centric approach reinforces Caris's mission to bridge the gap between technological advancements and patient care.
A Comprehensive Diagnostic Tool
MI Cancer Seek operates using next-generation sequencing (NGS) and utilizes total nucleic acid obtained from formalin-fixed paraffin-embedded (FFPE) tumor specimens for the detection of various critical parameters in cancer patients. This includes identifying single nucleotide variants (SNVs), insertions and deletions (indels), as well as assessing microsatellite instability (MSI) and tumor mutational burden (TMB). Additionally, for breast cancer patients, MI Cancer Seek also evaluates copy number amplification (CNA) in one specific gene.
This diagnostic tool is designed to complement targeted therapies, ensuring that healthcare professionals can formulate a more informed treatment plan based on the molecular makeup of each patient's tumor. It aligns with professional oncology guidelines, further establishing MI Cancer Seek as an essential resource for oncologists.
About Caris Life Sciences
Caris Life Sciences is committed to transforming healthcare through advanced technology and innovation. As a leading next-generation AI TechBio company, Caris leverages comprehensive molecular profiling, advanced AI, and machine learning algorithms to develop solutions that enhance detection, diagnosis, and treatment of diseases. Their dedication to advancing precision medicine has resulted in the creation of a vast clinico-genomic database and a platform that provides cutting-edge diagnostic solutions.
Founded on the vision of integrating extensive molecular information with actionable insights, Caris strives to realize the promise of personalized medicine. With headquarters in Texas and locations across the globe, including offices in Phoenix, New York, and Tokyo, Caris continues to expand its reach and impact in the field of oncology.
Frequently Asked Questions
What is MI Cancer Seek®?
MI Cancer Seek is an FDA-approved assay combining whole exome and transcriptome sequencing to identify cancer patients who can benefit from targeted therapies.
How does MI Cancer Seek improve patient outcomes?
The assay enhances diagnostic accuracy by detecting multiple significant variants, ultimately leading to more personalized and effective treatment plans.
What are the advantages of using MI Cancer Seek over other assays?
MI Cancer Seek allows for simultaneous RNA and DNA extraction from minimal tissue samples, improving efficiency and reducing necessary patient tissue volume.
Who developed MI Cancer Seek?
MI Cancer Seek was developed by Caris Life Sciences, a leader in precision medicine accredited for its innovative approach in cancer diagnostics.
How can healthcare professionals access MI Cancer Seek results?
Healthcare professionals can utilize the results from MI Cancer Seek in conjunction with established oncology guidelines for formulating patient treatment plans.
